Citations

Showing 10 of 107941 citations.

The effect of pre-transplant and transplant care on organ quality: a cross-sectional study
Latifi, Marzieh , Rahban, Habib , Pourhossein, Elahe, Khalilzadeh, Mina, Dehghani, Sanaz , Latifi, Marzieh , Amin, Ahmad

Mayo Clinic

Frontiers of Nursing | September 25, 2025 | Volume: 12 | Issue: 3 | Pages: 375-381

10.2478/fon-2025-0041 Get It

Abstract Objective To determine the effect of management before and during transplantation on the quality of donated organs. Improvement of preservation methods in cases involving brain death will lead to more effective organ procurement. Methods Data were collected from the 226 brain death cases enrolled in the 12-month study period. All cases, patients with a Glasgow Coma Scale (GCS) score of 3 points, appropriate age, and having medical indications for organ donation, were considered to confirm the criteria of brain death. Transplant outcome data were obtained from the transplant centers. Results The age of the deceased ranged between 1 year and 68 years, with a mean ± SD of 39.54 ± 17.28 years. There was no significant difference between the quality of organs regarding blood group and cause of brain death ( P > 0.05). However, there was a significant difference in the quality of organs regarding age, body mass index (BMI), and gender. There was a significant difference between the level of urea at admission time and procurement time ( P < 0.001), as well as between creatinine level at admission time and procurement time ( P < 0.001). There was also a significant difference between aspartate aminotransferase (AST) at admission time and procurement time ( P < 0.001), and between alanine aminotransferase (ALT) at admission time and procurement time ( P < 0.001). Conclusions Transplant outcomes using older donor livers and kidneys were comparable to those using younger or male donors. These findings provide further evidence that decision-making about organ quality is influenced by age and gender and emphasize the importance of transparency in organ acceptance practices.
Calcium Intake and Bone Mineral Density in People With HIV and/or Chronic Hepatitis C
Temesgen, Zoey B , Temesgen, Zelalem , Bedimo, Roger , Bedimo, Roger J , Temesgen, Zelelem

Mayo Clinic

Open Forum Infectious Diseases | September 25, 2025 | Volume: 12 | Issue: 9 | Pages: No page available

10.1093/ofid/ofaf562 | PMID 41018712 Get It

Abstract Background Increased prevalence of reduced bone mineral density (BMD) is well documented in persons infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or both. This study's purpose was to determine if an association exists between dietary calcium intake and BMD in these patients. Methods Participants were individuals with virologically suppressed HIV or untreated HCV monoinfections, those with HIV/HCV coinfection, and noninfected controls. The Hertzler-Frary dietary calcium questionnaire documented calcium intake with calcium amounts based on the US Department of Agriculture nutrient database. BMD was measured at baseline by dual-energy x-ray absorptiometry, and χ2 tests were used to assess the relationship between BMD and infection status. One-way analysis of covariance was used to compare calcium intake data with the prevalence of normal BMD and osteoporosis by infection group. Adjustments were made for race, age, body mass index, and smoking status. Spearman correlation was used to identify relationships between calcium intake from foods/beverages and BMD. Results A total of 452 men were recruited into the study. Osteoporosis and osteopenia were prevalent, but there was no association between infection group and BMD result (χ2(6) = 6.813; P = .34). Only HCV-infected patients with osteoporosis had lower calcium intake than patients with normal BMD (mean difference, 409 mg/d [95% confidence interval, 35–784 mg/d]; P = .03). Conclusions In this study population, dietary calcium intake was correlated with reduced BMD only in patients with HCV monoinfection.
Intracranial Occlusion in Cryptogenic Stroke Is Not Predictive of Recurrent Ischemic Stroke: A Propensity‐Score Matched Analysis of the Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study
Brorson, James R. , Badillo‐Goicoechea, Elena , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M. , Khasiyev, Farid , Kerrigan, Deborah , Lewis, Skylar, Ali, Hamid , Melkumova, Emiliya , Dumitrascu, Oana M. , Parikh, Parth , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Brown, Samantha , Kang, Jieun, Bowman, Anna, Shahrivari, Mahan, Sehgal, S , Alvi, Muhammad , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Qdais, Ahmad Abu, Quintela, Gustavo Antezana, Sharma, Richa, Thottempudi, Neeharika, Nedelcu, Simona , Herpich, Franziska , Glover, Patrick , Chahien, Dalia, Liebeskind, David S. , Linares, Guillermo , Daniel, Jean‐Philippe, Kasab, Sami Al , Singh, Eesha , D’Souza, Maria , Gaudio, Elizabeth, Kala, Narendra , Sarkar, Monica , Coevering, Russell J. Van , Thon, Jesse , Thompson, Sean, Lineback, Christina , Brorson, James R , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M , Khasiyev, Farid , Kerrigan, Deborah , Ali, Hamid , Aboul-Nour, Hassan , de Havenon, Adam H , Culbertson, Collin J , Melkumova, Emiliya , Jillella, Dinesh V , Dumitrascu, Oana M , Parikh, Parth , Sathya, Anvitha , Brown, Samantha J , Elangovan, Cheran , Sehgal, Siddharth , Sloane, Kelly L , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Farooqui, Mudassir , Nahab, Fadi B , Sharma, Richa , Nedelcu, Simona , Herpich, Franziska , Liebeskind, David S. , Linares, Guillermo , Al Kasab, Sami , Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric D , Van Coevering, Russell J , Thon, Jesse , Stamm, Brian , Siegler, James E , Lineback, Christina M , Daniel, Jean-Philippe Auguste , Smith, Matthew M. , Nour, Hassan Aboul , Havenon, Adam de , Jillella, Dinesh , Doolittle, Charles, Elangovan, Cheran , Sharma, Richa , Thottempudi, Neeharika , D'Souza, Marissa, Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric , Chen, Lucia , Stamm, Brian , Siegler, James E.

Mayo Clinic

Journal of the American Heart Association | September 25, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.041500 | PMID 40996035 Get It

Background Intracranial occlusions in embolic stroke of undetermined source are histopathologically similar to cardiac sources of embolism. Whether patients with embolic stroke of undetermined source and intracranial occlusion benefit from anticoagulation is unknown. Methods A multicenter retrospective cohort of adults with cryptogenic stroke was queried for patients with proximal or medium/distal vessel occlusion. The primary outcome was recurrent ischemic stroke, which was assessed in unadjusted and adjusted Cox proportional hazards models and repeated following 1:1 propensity score matching and biweight kernel density matching. Results Of the 2328 patients who were followed over a median of 1.31 years (interquartile range, 0.34–2.85), 999 (42.6%) had an intracranial occlusion. When compared with patients without an intracranial occlusion, those with an occlusion had fewer atherosclerotic vascular risk factors, more severe symptoms, and less severe cerebral microvascular disease. The rate of recurrent stroke was similar between patients with versus without an intracranial occlusion (6.8%/year [95% CI, 5.7–8.2] versus 7.0%/year [95% CI 6.0–8.1]; adjusted hazard ratio [HR], 1.09 [95% CI, 0.77–1.55]). There was no association between occlusion and recurrent stroke in the adjusted propensity score matching (HR, 1.01 [95% CI, 0.64–1.59]) or kernel density models (HR, 0.95 [95% CI, 0.62–1.45]). There was no interaction between occlusion and treatment with anticoagulation, sex, age, or high‐risk sources of embolism for the primary outcome in the unmatched and matched analyses. Conclusions Intracranial occlusion in patients with embolic stroke of undetermined source is not associated with a greater risk of recurrence when compared with patients without an intracranial occlusion. There was no difference in rate of recurrent stroke with anticoagulation when stratified by presence or absence of occlusion.
Isolated Polyethylene Exchange in Revision Total Knee Arthroplasty: A Review of Indications and Outcomes
Moses, Alex M. , Cushing, Melissa M. , Fawcett, Mason A. , Dohse, Nicolas, Adigweme, Obinna O., Ledford, Cameron K. , Ledford, Cameron K

Mayo Clinic

Journal of Clinical Medicine | September 25, 2025 | Volume: 14 | Issue: 19 | Pages: 6779

10.3390/jcm14196779 | PMID 41095857 Get It

Introduction: The use of modular components provides several advantages in total knee arthroplasty (TKA), including exchange of the polyethylene insert while retaining the stable components in the revision TKA. Compared to full, non-modular component revision TKA, isolated polyethylene exchange (IPE) has the advantage of decreased morbidity, faster rehabilitation, and acceptable outcomes. Methods: A review of published literature on revision TKA was conducted, with a specific focus on studies evaluating the use of IPE for managing complications such as stiffness, instability, and periprosthetic joint infection (PJI). Results: IPE with downsizing may be considered for patients with mild stiffness and stable, well-positioned implants that have increased polyethylene thickness, though expectations for motion gain should be cautious. There is no clear consensus on IPE for instability. Some studies report high re-revision rates, while others show clinical and functional improvement when the TKA is well-aligned, well-fixed, and intraoperative gap balance is achieved. Additionally, irrigation and debridement with polyethylene exchange (IDPE) may be effective for acute TKA PJI management, particularly within the first two weeks of symptom onset. Conclusions: Based on current literature, IPE in aseptic TKA revisions may be effective for stiffness or instability when implants are well-fixed and well-aligned—particularly if polyethylene constraint can be adjusted for instability or downsized for stiffness. The role of IDPE in acute TKA PJI is better defined in the literature, with strong emphasis on its time-sensitive effectiveness—most notably within the first two weeks of symptom onset.
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy
Caldera, Freddy , Mogallapalli, Harshitha, Abusalim, Abdulrahman , Caldera, Freddy , Farraye, Francis A. , Hayney, Mary S.

Mayo Clinic

Clinical and Translational Gastroenterology | September 25, 2025 | Volume: 16 | Issue: 11 | Pages: e00924

10.14309/ctg.0000000000000924 | PMID 40995992 Get It

INTRODUCTION: Patients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster and should receive the recombinant herpes zoster vaccine (RZV). We sought to assess the immunogenicity and safety of RZV series in patients receiving anti-tumor necrosis factor (TNF) therapy compared with those receiving vedolizumab. METHODS: This single-center prospective study enrolled patients with IBD on vedolizumab or anti-TNF monotherapy receiving RZV. Primary outcome assessed cell-mediated immunity (CMI) differences between groups postvaccination. Secondary outcomes included humoral response, sustained immunity, and safety monitoring for adverse events and IBD flares. Assessments occurred at baseline, 30, 240, and 425 days postvaccination. Statistical analyses included nonparametric Mann-Whitney U tests for between-group comparisons and Wilcoxon signed-rank tests for within-group changes, with significance set at P < 0.05. RESULTS: Thirty-three patients enrolled (16 vedolizumab, 17 anti-TNF). CMI responses increased postvaccination in both groups (median 56 cells/million [interquartile range {IQR} 21–102] vs 33 cells/million [IQR 11–73]; P = 0.13), with no significant difference between treatment groups. Both groups showed strong antibody responses to vaccination (preimmunization median: 349.9 mIU/mL [IQR 276.8–402.5] vs 90-day median: 605.0 mIU/mL [IQR 525.6–641.0]; P < 0.001). CMI responses remained elevated at both day 240 and 425 assessments. Antibody levels remained elevated through day 425 (549.1 mIU/mL, IQR 516.1–585.6), substantially higher than prevaccination levels. No IBD flares occurred; most adverse events were mild and transient. DISCUSSION: RZV demonstrated robust immunogenicity and favorable safety profile in patients with IBD receiving either vedolizumab or anti-TNF therapy. Both cellular and humoral immune responses persisted through 425 days postvaccination.
A Rare CRTC1::NCOA2 Gene Fusion With a Novel NCOA2 Rearrangement in a Pediatric Patient With an Epithelioid Mesenchymal Neoplasm of the Spinal Cord
Nourani, Mona , Tiwari, Nishant , Tola, Eduardo Zambrano, Vaughn, Jennifer, Sivakumaran, Theru A. , Azab, Bilal, Keole, Sameer R., Mangum, Ross , Mangum, Ross , Azab, Bilal

Mayo Clinic

Journal of Pediatric Hematology/Oncology | September 25, 2025 | Volume: 47 | Issue: 7 | Pages: e297-e304

10.1097/mph.0000000000003094 Get It

We present the case of a 12-year-old female who presented with progressive back pain and was found to have a localized mass in the lumbar spine. The resected tissue was characterized by epithelioid cells with a papillary appearance and high mitotic activity. Initial immunohistochemical analysis was consistent with a diagnosis of atypical meningioma. However, comprehensive molecular profiling detected a CRTC1::NCOA2 fusion with a novel NCOA2 gene rearrangement, leading to a revised descriptive diagnosis of epithelioid mesenchymal neoplasm with CRTC1::NCOA2 fusion. This specific fusion has only been reported in 2 other cases involving mesenchymal neoplasms of the palate and urinary bladder. While CRTC1 is frequently associated with MAML2 fusion in mucoepidermoid carcinomas, NCOA2 rearrangements occur in a variety of solid and hematologic malignancies. There is a paucity of information on the prognostic relevance of these fusion partners. This is the first reported case of a CRTC1::NCOA2 fusion in a pediatric patient with a spinal cord malignancy. The mechanistic significance and prognostic implications of this fusion will be discussed.
Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index
Vargas-Brochero, Maria J. , Russo, Ilario , Mazzierli, Tommaso , Cara, Anila, Berti, Gian Marco , Milheiro, Joaquim , Thongprayoon, Charat, Allinovi, Marco , Somma, Chiara , Raglianti, Valentina , D’Arpino, Emanuele , Zand, Ladan , Núñez, Sara , Soler, María José , Sethi, Sanjeev , Gutiérrez, Eduardo, Praga, Manuel , Núñez-Delgado, Sara , Caravaca-Fontán, Fernando , Romagnani, Paola , Fervenza, Fernando C , Soler, Maria Jose , Thongprayoon, Charat , Caravaca‐Fontán, Fernando , Romagnani, Paola , Fervenza, Fernando C.

Mayo Clinic

Nephrology Dialysis Transplantation | September 25, 2025 | Volume: 41 | Issue: 4 | Pages: 703-714

10.1093/ndt/gfaf197 | PMID 40996459 Get It

ABSTRACT Background Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are emerging as an essential part of the standard of care for proteinuria in patients with chronic kidney disease. To date, no study has specifically evaluated the effects of body mass index (BMI) on the antiproteinuric efficacy of SGLT2is. Here we report the impact of BMI on the antiproteinuric efficacy of SGLT2is in non-diabetic patients with glomerular diseases. Methods This is a retrospective, multicentre, international observational cohort study that included non-diabetic patients with biopsy-proven glomerular disease and proteinuria &gt;0.5 g/24 h who received SGLT2is between 2016 and 2023. Laboratory values, including proteinuria and estimated glomerular filtration rate (eGFR), were obtained at baseline and after 3–6 months. Changes in laboratory values over time were analysed using the paired signed-rank test. Results A total of 300 patients met the inclusion criteria. The median age was 51.82 years [interquartile range (IQR) 41–62.65], 64.7% were male and 92.7% were white. The most common glomerular disease was immunoglobulin A nephropathy (40.3%). The median eGFR was 52.26 ml/min/1.73 m2 (IQR 36.41–74.01), the median proteinuria was 1.60 g/24 h (IQR 1.15–2.91) and the median serum albumin was 4.08 g/dl (IQR 3.80–4.30). Proteinuria reduction after SGLT2i initiation was significant only in overweight and obese patients (P &lt; .001 versus 0.18). Patients with normal BMI did not experience the expected early decrease in eGFR (P = .16). Conclusions SGLT2is are ineffective in proteinuria reduction in patients with a BMI &lt;25 kg/m2, which contrasts with the significant proteinuria reduction in overweight and obese patients with glomerulopathies.
Steroid-responsive encephalopathy associated with autoimmune thyroiditis
Wells, Mathew, Rife, Jared, Nafziger, Elizabeth, Hopkins, Samantha, Wells, Mathew, Hopkins, Samantha

Mayo Clinic

BMJ Case Reports | September 25, 2025 | Volume: 18 | Issue: 9 | Pages: e268082

10.1136/bcr-2025-268082 | PMID 40998544 Get It

Hashimoto encephalopathy or steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) is a rare condition associated with rapidly progressive dementia, stroke-like symptoms, psychosis and positive antithyroid antibodies. In this case report, a woman in her 80s with hypothyroidism and no other medically relevant history presented with a 2-week complaint of progressive hallucinations, short-term memory loss and paranoia. Eventually hospitalised, her hospital course was complicated by severe hospital-acquired delirium, which clouded the clinical picture; however, initial workup revealed an elevated thyroglobulin antibody and thyroid peroxidase, both highly specific for SREAT. A 3-day course of high-dose methylprednisolone (1 g/day) was administered, which revealed marked improvement in patient symptoms. Definitive treatment included a 13-week oral prednisone taper and outpatient follow-up with neurology and primary care. In cases of new onset neuropsychiatric symptoms in geriatric populations, SREAT is a reversible, must-not-miss diagnosis, when treated with systemic steroids.
Safety and efficacy of the ShangRing for early infant male circumcision in the routine clinical setting
Calderon, Lina Posada , Ho, Kaylee, Barone, Mark A. , Awori, Quentin , Ouma, Daniel, Oketch, Jairus, Christensen, Alice, Hellar, Augustino , Makokha, Maende, Isangu, Alphonce, Salim, Robert, Lija, Jackson, Gray, Ronald H. , Kiboneka, Stephen, Anok, Aggrey , Kigozi, Godfrey , Nakabuye, Regina, Ddamulira, Charles, Odiya, Silas, Goldstein, Marc , Li, Philip S. , Lee, Richard K. , Posada Calderon, Lina , Basourakos, Spyridon P. , Hellar, Augustino , Ballman, Karla V.

Mayo Clinic

BMJ Global Health | September 25, 2025 | Volume: 10 | Issue: 9 | Pages: e017903

10.1136/bmjgh-2024-017903 | PMID 40998526 Get It

Introduction Male circumcision (MC) has been shown to decrease transmission of HIV and is a critical strategy to decrease its incidence in countries with high rates of heterosexually transmitted HIV. Early infant MC (EIMC), with single-use MC devices, could increase rates of MC in Sub-Saharan Africa. Our objective was to determine the safety, efficacy and satisfaction of ShangRing EIMC in resource-constrained environments. Methods Healthy male infants aged 1–60 days underwent ShangRing EIMC performed by non-physician clinicians in 14 sites in Kenya, Tanzania and Uganda. The primary outcomes were the safety and efficacy of ShangRing EIMC. Secondary outcomes were pain related to the procedure, wound healing and parental satisfaction. Male infants were assessed at discharge and on postoperative days 7 and 28 for wound healing and complications. This trial is registered with Clinical.Trials.gov, NCT03338699 , and is complete. Results From the 1697 participants enrolled from February to November 2020, 1691 (99.6%) underwent ShangRing EIMC. Median duration of the procedure was 10 min (IQR 6–13). The mean Neonatal Infant Pain Scale 20 min postprocedure was 0.3 (SD 0.8), indicating no pain. At the time of discharge, 1679 (99.0%) participants had a normal-appearing wound and 1574 (93.1%) demonstrated complete wound healing at 28 days. A total of 17 (1.0%) AEs were reported, most related to bleeding. A total of 1635 (99.1%) of parents were satisfied with the appearance of the circumcised penis at 28 days. Conclusion ShangRing EIMC is a simple and successful MC method that non-physician clinicians can perform safely, with low AE rate, satisfactory wound healing and high satisfaction rate among parents. This indicates that the ShangRing EIMC can be considered a long-term strategic approach to accelerate the scale-up of MC in Sub-Saharan Africa. Trial registration number NCT03338699 .